Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.




[Back to Overview]  [IACM Homepage]

TitleProof of concept trial of dronabinol in obstructive sleep apnea.
Author(s)Prasad B, Radulovacki MG, Carley DW.
Journal, Volume, IssueFront Psychiatry 2013;4:1.
Major outcome(s)THC significantly improved this condition.
IndicationSpasticityAbstract
MedicationDelta-9-THC

STUDY OBJECTIVE: Animal data suggest that Δ(9)-TetraHydroCannabinol (Δ(9)THC) stabilizes autonomic output during sleep, reduces spontaneous sleep-disordered breathing, and blocks serotonin-induced exacerbation of sleep apnea. On this basis, we examined the safety, tolerability, and efficacy of dronabinol (Δ(9)THC), an exogenous Cannabinoid type 1 and type 2 (CB1 and CB2) receptor agonist in patients with Obstructive Sleep Apnea (OSA). DESIGN AND SETTING: Proof of concept; single-center dose-escalation study of dronabinol.
PARTICIPANTS: Seventeen adults with a baseline Apnea Hypopnea Index (AHI) ≥15/h. Baseline polysomnography (PSG) was performed after a 7-day washout of Continuous Positive Airway Pressure treatment.
INTERVENTION: Dronabinol was administered after baseline PSG, starting at 2.5 mg once daily. The dose was increased weekly, as tolerated, to 5 mg and finally to 10 mg once daily.
MEASUREMENTS AND RESULTS: Repeat PSG assessments were performed on nights 7, 14, and 21 of dronabinol treatment. Change in AHI (ΔAHI, mean ± SD) was significant from baseline to night 21 (-14.1 ± 17.5; p = 0.007). No degradation of sleep architecture or serious adverse events was noted. CONCLUSION: Dronabinol treatment is safe and well-tolerated in OSA patients at doses of 2.5-10 mg daily and significantly reduces AHI in the short-term. These findings should be confirmed in a larger study in order to identify sub-populations with OSA that may benefit from cannabimimetic pharmacologic therapy.

Route(s)Oral
Dose(s)
Duration (days)
Participants17 patients suffereding from sleep apnoea
DesignOpen study
Type of publicationMedical journal
Address of author(s)Department of Medicine, University of Illinois at Chicago Chicago, IL, USA.
Full textwww.ncbi.nlm.nih.gov/pubmed/23346060

[Back to Overview]  [IACM Homepage]


up